Incidence and risk factors of nephrotoxicity in patients on colistimethate sodium

Moataz M. Hassan, Zied Gaifer, Ibrahim S. Al-Zakwani

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background Colistin is used to treat gram-negative infections but it’s highly associated with nephrotoxicity. Objectives To determine the incidence and risk factors as well as mortality in patients on colistin. Setting Sultan Qaboos University Hospital, Muscat, Oman. Methods This was a retrospective cohort study of patients admitted and who received colistin for ≥ 48 h. The exclusion criteria included inhaled colistin therapy, cystic fibrosis, or pregnancy. The study period was from January 2010 to June 2016. Main outcome measures Nephrotoxicity using the Risk, Injury, Failure, Loss and Endstage kidney disease (RIFLE) criteria. The secondary outcomes were incidence, risk factors and mortality in patients on colistin. Results A total of 123 patients were included. Colistin-associated nephrotoxicity (CAN) occurred in 57 (46%) patients after colistin therapy. As per the RIFLE criteria, 22 (18%) patients were classified as ‘at risk’, 17 (14%) as ‘injury’, and 18 (15%) as ‘failure’. Multivariate analysis indicated that increasing age (adjusted odds ratio (aOR), 1.03; 95% confidence interval (CI) 1.01–1.06; p = 0.004) and higher APACHE II score (aOR 1.08; 95% CI 1.01–1.16; p = 0.040) were significant predictors for the development of nephrotoxicity. Factors associated with mortality included ICU admission (aOR 23.3; 95% CI 5.04–106; p < 0.001), vasopressin use (aOR 5.54; 95% CI 1.56–19.6; p = 0.008) and higher APACHE II score (aOR 1.15; 95% CI 1.03–1.30; p = 0.027). Conclusions The incidence of CAN was 46%. Increasing age and higher APACHE II score were the risk factors for CAN. Factors associated with mortality at 28 days included ICU admission and higher APACHE II score.

Original languageEnglish
Pages (from-to)1-6
Number of pages6
JournalInternational Journal of Clinical Pharmacy
DOIs
Publication statusAccepted/In press - Mar 14 2018

Fingerprint

Colistin
Incidence
APACHE
Odds Ratio
Confidence Intervals
Intensive care units
Mortality
Oman
colistinmethanesulfonic acid
Wounds and Injuries
Kidney Diseases
Vasopressins
Cystic Fibrosis
Cohort Studies
Multivariate Analysis
Retrospective Studies
Outcome Assessment (Health Care)
Pregnancy

Keywords

  • Colistimethate sodium
  • Colistin
  • Gram-negative bacteria
  • Nephrotoxicity
  • Oman

ASJC Scopus subject areas

  • Pharmacy
  • Toxicology
  • Pharmacology
  • Pharmaceutical Science
  • Pharmacology (medical)

Cite this

Incidence and risk factors of nephrotoxicity in patients on colistimethate sodium. / Hassan, Moataz M.; Gaifer, Zied; Al-Zakwani, Ibrahim S.

In: International Journal of Clinical Pharmacy, 14.03.2018, p. 1-6.

Research output: Contribution to journalArticle

@article{5dfa73e1d74f499a9d53bd0f3fefc2ed,
title = "Incidence and risk factors of nephrotoxicity in patients on colistimethate sodium",
abstract = "Background Colistin is used to treat gram-negative infections but it’s highly associated with nephrotoxicity. Objectives To determine the incidence and risk factors as well as mortality in patients on colistin. Setting Sultan Qaboos University Hospital, Muscat, Oman. Methods This was a retrospective cohort study of patients admitted and who received colistin for ≥ 48 h. The exclusion criteria included inhaled colistin therapy, cystic fibrosis, or pregnancy. The study period was from January 2010 to June 2016. Main outcome measures Nephrotoxicity using the Risk, Injury, Failure, Loss and Endstage kidney disease (RIFLE) criteria. The secondary outcomes were incidence, risk factors and mortality in patients on colistin. Results A total of 123 patients were included. Colistin-associated nephrotoxicity (CAN) occurred in 57 (46{\%}) patients after colistin therapy. As per the RIFLE criteria, 22 (18{\%}) patients were classified as ‘at risk’, 17 (14{\%}) as ‘injury’, and 18 (15{\%}) as ‘failure’. Multivariate analysis indicated that increasing age (adjusted odds ratio (aOR), 1.03; 95{\%} confidence interval (CI) 1.01–1.06; p = 0.004) and higher APACHE II score (aOR 1.08; 95{\%} CI 1.01–1.16; p = 0.040) were significant predictors for the development of nephrotoxicity. Factors associated with mortality included ICU admission (aOR 23.3; 95{\%} CI 5.04–106; p < 0.001), vasopressin use (aOR 5.54; 95{\%} CI 1.56–19.6; p = 0.008) and higher APACHE II score (aOR 1.15; 95{\%} CI 1.03–1.30; p = 0.027). Conclusions The incidence of CAN was 46{\%}. Increasing age and higher APACHE II score were the risk factors for CAN. Factors associated with mortality at 28 days included ICU admission and higher APACHE II score.",
keywords = "Colistimethate sodium, Colistin, Gram-negative bacteria, Nephrotoxicity, Oman",
author = "Hassan, {Moataz M.} and Zied Gaifer and Al-Zakwani, {Ibrahim S.}",
year = "2018",
month = "3",
day = "14",
doi = "10.1007/s11096-018-0607-y",
language = "English",
pages = "1--6",
journal = "International Journal of Clinical Pharmacy",
issn = "2210-7703",
publisher = "Springer Netherlands",

}

TY - JOUR

T1 - Incidence and risk factors of nephrotoxicity in patients on colistimethate sodium

AU - Hassan, Moataz M.

AU - Gaifer, Zied

AU - Al-Zakwani, Ibrahim S.

PY - 2018/3/14

Y1 - 2018/3/14

N2 - Background Colistin is used to treat gram-negative infections but it’s highly associated with nephrotoxicity. Objectives To determine the incidence and risk factors as well as mortality in patients on colistin. Setting Sultan Qaboos University Hospital, Muscat, Oman. Methods This was a retrospective cohort study of patients admitted and who received colistin for ≥ 48 h. The exclusion criteria included inhaled colistin therapy, cystic fibrosis, or pregnancy. The study period was from January 2010 to June 2016. Main outcome measures Nephrotoxicity using the Risk, Injury, Failure, Loss and Endstage kidney disease (RIFLE) criteria. The secondary outcomes were incidence, risk factors and mortality in patients on colistin. Results A total of 123 patients were included. Colistin-associated nephrotoxicity (CAN) occurred in 57 (46%) patients after colistin therapy. As per the RIFLE criteria, 22 (18%) patients were classified as ‘at risk’, 17 (14%) as ‘injury’, and 18 (15%) as ‘failure’. Multivariate analysis indicated that increasing age (adjusted odds ratio (aOR), 1.03; 95% confidence interval (CI) 1.01–1.06; p = 0.004) and higher APACHE II score (aOR 1.08; 95% CI 1.01–1.16; p = 0.040) were significant predictors for the development of nephrotoxicity. Factors associated with mortality included ICU admission (aOR 23.3; 95% CI 5.04–106; p < 0.001), vasopressin use (aOR 5.54; 95% CI 1.56–19.6; p = 0.008) and higher APACHE II score (aOR 1.15; 95% CI 1.03–1.30; p = 0.027). Conclusions The incidence of CAN was 46%. Increasing age and higher APACHE II score were the risk factors for CAN. Factors associated with mortality at 28 days included ICU admission and higher APACHE II score.

AB - Background Colistin is used to treat gram-negative infections but it’s highly associated with nephrotoxicity. Objectives To determine the incidence and risk factors as well as mortality in patients on colistin. Setting Sultan Qaboos University Hospital, Muscat, Oman. Methods This was a retrospective cohort study of patients admitted and who received colistin for ≥ 48 h. The exclusion criteria included inhaled colistin therapy, cystic fibrosis, or pregnancy. The study period was from January 2010 to June 2016. Main outcome measures Nephrotoxicity using the Risk, Injury, Failure, Loss and Endstage kidney disease (RIFLE) criteria. The secondary outcomes were incidence, risk factors and mortality in patients on colistin. Results A total of 123 patients were included. Colistin-associated nephrotoxicity (CAN) occurred in 57 (46%) patients after colistin therapy. As per the RIFLE criteria, 22 (18%) patients were classified as ‘at risk’, 17 (14%) as ‘injury’, and 18 (15%) as ‘failure’. Multivariate analysis indicated that increasing age (adjusted odds ratio (aOR), 1.03; 95% confidence interval (CI) 1.01–1.06; p = 0.004) and higher APACHE II score (aOR 1.08; 95% CI 1.01–1.16; p = 0.040) were significant predictors for the development of nephrotoxicity. Factors associated with mortality included ICU admission (aOR 23.3; 95% CI 5.04–106; p < 0.001), vasopressin use (aOR 5.54; 95% CI 1.56–19.6; p = 0.008) and higher APACHE II score (aOR 1.15; 95% CI 1.03–1.30; p = 0.027). Conclusions The incidence of CAN was 46%. Increasing age and higher APACHE II score were the risk factors for CAN. Factors associated with mortality at 28 days included ICU admission and higher APACHE II score.

KW - Colistimethate sodium

KW - Colistin

KW - Gram-negative bacteria

KW - Nephrotoxicity

KW - Oman

UR - http://www.scopus.com/inward/record.url?scp=85043712977&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043712977&partnerID=8YFLogxK

U2 - 10.1007/s11096-018-0607-y

DO - 10.1007/s11096-018-0607-y

M3 - Article

AN - SCOPUS:85043712977

SP - 1

EP - 6

JO - International Journal of Clinical Pharmacy

JF - International Journal of Clinical Pharmacy

SN - 2210-7703

ER -